Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Ironwood Pharmaceuticals (IRWD) but lowers the price target from $18 to $14.

May 10, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Craig-Hallum analyst maintains a Buy rating on Ironwood Pharmaceuticals but lowers the price target from $18 to $14, indicating a positive outlook but adjusting expectations.
The maintenance of a Buy rating suggests a positive outlook on IRWD by Craig-Hallum, indicating confidence in the company's future performance. However, the reduction in the price target from $18 to $14 reflects an adjustment in expectations, possibly due to market conditions or company-specific factors not detailed in the news. This could lead to mixed reactions in the short term, as investors weigh the positive rating against the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100